FDA Announcement: A pivotal time for the health of women

FDA Announcement: A pivotal time for the health of women

10 November 2025 marks a momentous time in history for women. The Food and Drug Administration (FDA) commissioner Dr Marty Makary has announced in a public meeting that the warnings for estrogen products in hormone replacement therapy (HRT) and vaginal hormones are going to be removed.

For decades, the warnings of breast cancer, cardiovascular disease and dementia have been needlessly scaring women away from being prescribed hormones.

Much of this fear stems from the ill-fated Women’s Health Initiative (WHI) study, which was a billion dollar study that was halted early due to perceived risks of (HRT). Some of the researchers wrote a press release that went to the mainstream media and to the medical press before this study was analysed properly. The headlines were that “HRT causes breast cancer” and “HRT causes heart attacks” so women across the world were actively encouraged to stop taking HRT.

HRT prescribing literally fell off a cliff – before the study around 40% of menopausal women in the US and 30% of menopausal women in the UK were prescribed HRT and now it is around 4% and 14% respectively. This has resulted in millions of menopausal women suffering with symptoms and health risks with their low hormones.

Understanding the benefits of HRT

Even in 1941, it was discovered that women taking HRT had a lower future risk of developing osteoporosis – this is very significant as around one in two menopausal women have osteoporosis and around one in three menopausal women sustain a hip fracture due to osteoporosis.

In the 1970s, HRT was one of the most commonly prescribed drugs and there was increasing evidence reporting the many benefits of HRT – both for symptom improvement and for improving future health.

Women taking HRT have been shown to have a lower future risk of developing cardiovascular disease, including heart attacks and strokes, with some studies showing around a 50% risk reduction – so even better than results with statins.

The WHI also showed that women taking HRT had a dramatic reduction in bowel cancer and diabetes – both common conditions – yet this was largely ignored too.

Spreading fear among women

Most women are scared of HRT and most healthcare professionals are still refusing to prescribe HRT as they are scared about the perceived risk of breast cancer. But that is what it is – an alleged risk that has petrified women across the world with no good quality evidence to support this.

Even the WHI study – when analysed properly – showed a 24% reduction in risk of developing breast cancer in women taking oestrogen-only HRT and there has never been a study showing that women who take body identical hormones have a greater risk of developing breast cancer. After all, body identical hormones are the same structure as our own hormones so why would they cause cancer? It makes zero logical sense.

As menopausal women, we have been hoodwinked. As healthcare professionals, we have been deceived.

For many years, the more inquisitive and professionally curious clinicians amongst us have kept asking questions, challenging the statements, and even probing the authorities regarding the reasons for so many women being denied HRT without any good evidence.

We have been talking more openly about the harms of not prescribing HRT to women – the harms of symptoms, especially the mental health symptoms, the harms of future diseases occurring, the harms to home and family lives, the harms of leaving jobs due to symptoms such as memory problems, fatigue and anxiety, and the harms of simply being refused an evidence-based treatment.

Following the evidence

Yet the evidence has always been there – that hormones are safe and effective. Millions of women have been, and continue to be, harmed with scaremongering and misinformation about hormones.

We have heard in the meeting today that the science is clear – HRT is safe and effective and women’s health has been at risk and tens of millions of women have suffered needlessly.

Dr Marty Makary, Dr Rachel Rubins and Dr Kelly Casperson have all been on my podcast and it is a privilege to know them and watch them stand up and share their knowledge and passion for making a difference.

The future is brighter for women after this announcement – I hope other countries do the same and stop harming women with fear and deception about hormones.

Authored by Dr Louise Newson, BSc(Hons) MBChB(Hons) MRCP(UK) FRCGP, Founder of Newson Education

Recent Posts

DermaHub Launch

DermaHub Launch

On 1st November 2023, Derma Medical launched the world’s first e-learning hub for Aesthetics professionals. DermaHub will be the first of its kind to offer a subscription-based platform that will allow delegates to access the highest-quality online training from...

TAIC Meet-Up

TAIC Meet-Up

Karen O'Mahony attends The Alternative Investment Club's Meet-Up, LONGEVITY: Not Only Living Longer but Better PEAL's Managing Partner, Karen O'Mahony, thoroughly enjoyed sharing her insights on Longevity alongside the panel at The Alternative Investment Club's...

Private Equity International Operating Partners Forum

Private Equity International Operating Partners Forum

Karen O'Mahony spoke about building agility in the current economy and the next chapter of the value creation playbook at the PEI conference. At the Private Equity International Operating Partners Forum, Karen O'Mahony spoke about building agility in the current...

EisnerAmper Engaging Alternatives Podcast

EisnerAmper Engaging Alternatives Podcast

Karen O'Mahony appears on the EisnerAmper Engaging Alternatives Podcast Elana Margulise Snydeerman from the EisnerAmper Engaging Alternatives Podcast invited PEAL's Managing Partner Karen O'Mahony to share her outlook for lower mid-cap private equity investing. They...

Carmo Companies Private Markets Texas Conference

Carmo Companies Private Markets Texas Conference

Karen O'Mahony and Tara Mandal attended the Carmo Companies Private Markets Texas Conference during the PEAL US roadshow. Karen O'Mahony, Managing Partner and Tara Mandal, Partner and COO thoroughly enjoyed making new connections at Carmo Companies' Private Markets...

PEAL Capital Fund Investment

PEAL Capital Fund Investment

Female-founded private equity firm PEAL Capital Group acquires majority shareholding in leading aesthetic training provider Derma Medical. LONDON, UK, MAY 2022: Female-founded private equity firm PEAL Capital Group (“PEAL”) has acquired the UK’s number one cosmetic...

Derma Med Update Q2 2023

Derma Med Update Q2 2023

Derma Med continues to go from strength to strength, with strong growth across the UK, US and Australia. Since PEAL’s acquisition of Derma Med Ltd, the company has continued to go from strength to strength, with strong growth across the UK, US and Australia across all...